Guang Peng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4498496/publications.pdf

Version: 2024-02-01

32	2,353	394421 19	414414 32
papers	citations	h-index	g-index

33	33	33	4837
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature Medicine, 2018, 24, 556-562.	30.7	372
2	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discovery, 2015, 5, 752-767.	9.4	361
3	Genome-wide transcriptome profiling of homologous recombination DNA repair. Nature Communications, 2014, 5, 3361.	12.8	182
4	Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cellular Signalling, 2013, 25, 1086-1095.	3.6	180
5	BRIT1/MCPH1 links chromatin remodelling to DNA damage response. Nature Cell Biology, 2009, 11, 865-872.	10.3	175
6	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nature Medicine, 2021, 27, 141-151.	30.7	134
7	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 1699-1712.	7.0	95
8	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut, 2020, 69, 18-31.	12.1	94
9	Non-coding RNAs: An emerging player in DNA damage response. Mutation Research - Reviews in Mutation Research, 2015, 763, 202-211.	5.5	88
10	Chromodomain Helicase DNA-binding Protein 4 (CHD4) Regulates Homologous Recombination DNA Repair, and Its Deficiency Sensitizes Cells to Poly(ADP-ribose) Polymerase (PARP) Inhibitor Treatment. Journal of Biological Chemistry, 2012, 287, 6764-6772.	3.4	85
11	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature Communications, 2021, 12, 5606.	12.8	76
12	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. Journal of Clinical Investigation, 2020, 130, 5951-5966.	8.2	72
13	Human Nuclease/Helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection. Cancer Research, 2012, 72, 2802-2813.	0.9	63
14	DNA-Damage-Induced Nuclear Export of Precursor MicroRNAs Is Regulated by the ATM-AKT Pathway. Cell Reports, 2013, 3, 2100-2112.	6.4	58
15	YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut, 2021, 70, 55-66.	12.1	53
16	Nucleostemin deletion reveals an essential mechanism that maintains the genomic stability of stem and progenitor cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11415-11420.	7.1	48
17	Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World Journal of Clinical Oncology, 2011, 2, 73.	2.3	38
18	ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. Cancer Letters, 2020, 473, 148-155.	7.2	31

#	Article	IF	Citations
19	Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. Nature Communications, 2018, 9, 3982.	12.8	28
20	GRB2 enforces homology-directed repair initiation by MRE11. Science Advances, 2021, 7, .	10.3	21
21	Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Communications Biology, 2020, 3, 784.	4.4	21
22	Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinomaâ€"rationale for targeting ARID1A deficiency. Gut, 2022, 71, 467-478.	12.1	18
23	Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression. Oncogene, 2019, 38, 3919-3931.	5.9	11
24	Natural product Î²-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy. DNA Repair, 2017, 60, 89-101.	2.8	9
25	Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High-Throughput Image-Based Screening. SLAS Discovery, 2017, 22, 813-826.	2.7	8
26	The linkage of chromatin remodeling to genome maintenance: Contribution from a human disease gene BRIT1/MCPH1. Epigenetics, 2009, 4, 457-461.	2.7	7
27	Phosphorylation of the BRCA1 C Terminus (BRCT) Repeat Inhibitor of hTERT (BRIT1) Protein Coordinates TopBP1 Protein Recruitment and Amplifies Ataxia Telangiectasia-mutated and Rad3-related (ATR) Signaling. Journal of Biological Chemistry, 2014, 289, 34284-34295.	3.4	7
28	RADical Response Puts an Exceptional Responder in CHKmate: A Synthetic Lethal Curative Response to DNA-Damaging Chemotherapy?. Cancer Discovery, 2014, 4, 988-990.	9.4	5
29	Integrative Analysis Identifies Multi-Omics Signatures That Drive Molecular Classification of Uveal Melanoma. Cancers, 2021, 13, 6168.	3.7	5
30	Mathematical Model of Dynamic Protein Interactions Regulating p53 Protein Stability for Tumor Suppression. Computational and Mathematical Methods in Medicine, 2013, 2013, 1-6.	1.3	4
31	Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. American Journal of Cancer Research, 2020, 10, 3947-3972.	1.4	3
32	Dissect the Dynamic Molecular Circuits of Cell Cycle Control through Network Evolution Model. BioMed Research International, 2017, 2017, 1-9.	1.9	0